The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-04

AUTHORS

Aristotelis Bamias, Vasilios Karavasilis, Nikolaos Gavalas, Kimon Tzannis, Epaminontas Samantas, Gerasimos Aravantinos, Angelos Koutras, Ioannis Gkerzelis, Euthymios Kostouros, Konstantinos Koutsoukos, Flora Zagouri, George Fountzilas, Meletios-Athanasios Dimopoulos

ABSTRACT

BACKGROUND: Vascular endothelial growth factor (VEGF) targeting represents the standard first-line therapy for metastatic renal-cell carcinoma (mRCC), while blocking the mammalian target of rapamycin (mTOR) is effective in relapsed disease. Since continuing blockade of VEGF may be of value, we studied the combination of bevacizumab with temsirolimus in mRCC patients relapsing after first-line treatment. METHODS: A prospective, phase II study of the combination of bevacizumab (10 mg/kg, every 2 weeks) with temsirolimus (25 mg weekly) in patients with mRCC who failed first-line anti-VEGF treatment. 6-month progression-free survival (PFS) rate was the primary end point. The association of VEGFa, VEGFR2, fibroblast growth factor (FGF) b, platelet-derived growth factor receptor (PDGFR) a and PDGFRb with prognostic factors and outcomes were also studied. RESULTS: 39 patients were enrolled. First-line therapy included: sunitinib (n = 16), bevacizumab/interferon (n = 12), pazopanib (n = 10), sorafenib (n = 1). After a median follow-up of 37 months, 6-month PFS rate was 50.9% [95% confidence interval (CI) 33.8-65.7], median time to progression 6.8 months (95% CI 5.5-9.2) and median overall survival (OS) 18.2 months (95% CI 12.9-27.2). Objective response rate was 27%. The most common AEs were metabolic (33%), renal (8%) and gastrointestinal (GI) (7%). The most common grade 3-5 AEs were GI (18%), infections (14%) and metabolic (25%). Toxicity was the most frequent cause of treatment discontinuation (40%). FGFb levels were associated with OS. CONCLUSIONS: In concert with recent data, our study confirms the efficacy of anti-VEGF/anti-mTOR combination in mRCC relapsing after anti-VEGF therapy. Toxicity was considerable leading to high rate of treatment discontinuations. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01264341. More... »

PAGES

411-419

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10147-018-1361-9

DOI

http://dx.doi.org/10.1007/s10147-018-1361-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1107897433

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30374686


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "National and Kapodistrian University of Athens", 
          "id": "https://www.grid.ac/institutes/grid.5216.0", 
          "name": [
            "Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens, 80 Vas. Sofias Ave, 115 28, Athens, Greece"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bamias", 
        "givenName": "Aristotelis", 
        "id": "sg:person.01022220655.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01022220655.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Aristotle University of Thessaloniki", 
          "id": "https://www.grid.ac/institutes/grid.4793.9", 
          "name": [
            "Department of Medical Oncology, Papageorgiou Hospital, School of Health Sciences, Faculty of Medicine, Aristotle University of Thessaloniki, Thessalon\u00edki, Greece"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Karavasilis", 
        "givenName": "Vasilios", 
        "id": "sg:person.0654575012.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0654575012.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National and Kapodistrian University of Athens", 
          "id": "https://www.grid.ac/institutes/grid.5216.0", 
          "name": [
            "Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens, 80 Vas. Sofias Ave, 115 28, Athens, Greece"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gavalas", 
        "givenName": "Nikolaos", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National and Kapodistrian University of Athens", 
          "id": "https://www.grid.ac/institutes/grid.5216.0", 
          "name": [
            "Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens, 80 Vas. Sofias Ave, 115 28, Athens, Greece"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tzannis", 
        "givenName": "Kimon", 
        "id": "sg:person.01272512015.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01272512015.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Third Department of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Samantas", 
        "givenName": "Epaminontas", 
        "id": "sg:person.01326021733.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01326021733.68"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Aravantinos", 
        "givenName": "Gerasimos", 
        "id": "sg:person.0677251261.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0677251261.67"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Division of Oncology, Department of Medicine, University Hospital, University of Patras Medical School, Patras, Greece"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Koutras", 
        "givenName": "Angelos", 
        "id": "sg:person.01303065611.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01303065611.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Urology, General Hospital Konstantopouleio Agia Olga, Athens, Greece"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gkerzelis", 
        "givenName": "Ioannis", 
        "id": "sg:person.013652471530.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013652471530.87"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National and Kapodistrian University of Athens", 
          "id": "https://www.grid.ac/institutes/grid.5216.0", 
          "name": [
            "Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens, 80 Vas. Sofias Ave, 115 28, Athens, Greece"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kostouros", 
        "givenName": "Euthymios", 
        "id": "sg:person.013666511457.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013666511457.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National and Kapodistrian University of Athens", 
          "id": "https://www.grid.ac/institutes/grid.5216.0", 
          "name": [
            "Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens, 80 Vas. Sofias Ave, 115 28, Athens, Greece"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Koutsoukos", 
        "givenName": "Konstantinos", 
        "id": "sg:person.01332741603.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01332741603.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National and Kapodistrian University of Athens", 
          "id": "https://www.grid.ac/institutes/grid.5216.0", 
          "name": [
            "Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens, 80 Vas. Sofias Ave, 115 28, Athens, Greece"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zagouri", 
        "givenName": "Flora", 
        "id": "sg:person.0723540466.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723540466.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Aristotle University of Thessaloniki", 
          "id": "https://www.grid.ac/institutes/grid.4793.9", 
          "name": [
            "Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessalon\u00edki, Greece", 
            "Aristotle University of Thessaloniki, Thessalon\u00edki, Greece"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fountzilas", 
        "givenName": "George", 
        "id": "sg:person.0601312360.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601312360.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National and Kapodistrian University of Athens", 
          "id": "https://www.grid.ac/institutes/grid.5216.0", 
          "name": [
            "Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens, 80 Vas. Sofias Ave, 115 28, Athens, Greece"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dimopoulos", 
        "givenName": "Meletios-Athanasios", 
        "id": "sg:person.01046642035.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01046642035.29"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1056/nejmoa065044", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007947936"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2014.60.7341", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008993365"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2014.60.7341", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008993365"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(07)61904-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010511397"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1172/jci24612", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011051285"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2013.50.5305", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011437471"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1535-7163.mct-06-0071", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012687077"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/1759-7714.12202", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012855455"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdv170", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014223550"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1524-475x.2008.00410.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016786299"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1524-475x.2008.00410.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016786299"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(13)70093-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017252421"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.25219", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017587632"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.25219", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017587632"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1510665", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019970557"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/20459", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020261903", 
          "https://doi.org/10.1038/20459"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/20459", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020261903", 
          "https://doi.org/10.1038/20459"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.clgc.2016.02.007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020929346"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2011.11.027", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021703405"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-06-4102", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022228675"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(16)30107-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031150467"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(14)70030-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033030655"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ccr.2005.09.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040672904"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ccr.2005.09.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040672904"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0165-4608(96)00296-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040691028"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(08)61039-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045744105"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(11)70124-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046924268"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-014-2668-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047451975", 
          "https://doi.org/10.1007/s00280-014-2668-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3816/cgc.2008.n.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048226250"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(15)00290-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048871630"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.23.9764", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052849919"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.01.186", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064204187"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074847514", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079263967", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2016.70.7398", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083840373"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-04", 
    "datePublishedReg": "2019-04-01", 
    "description": "BACKGROUND: Vascular endothelial growth factor (VEGF) targeting represents the standard first-line therapy for metastatic renal-cell carcinoma (mRCC), while blocking the mammalian target of rapamycin (mTOR) is effective in relapsed disease. Since continuing blockade of VEGF may be of value, we studied the combination of bevacizumab with temsirolimus in mRCC patients relapsing after first-line treatment.\nMETHODS: A prospective, phase II study of the combination of bevacizumab (10\u00a0mg/kg, every 2\u00a0weeks) with temsirolimus (25\u00a0mg weekly) in patients with mRCC who failed first-line anti-VEGF treatment. 6-month progression-free survival (PFS) rate was the primary end point. The association of VEGFa, VEGFR2, fibroblast growth factor (FGF) b, platelet-derived growth factor receptor (PDGFR) a and PDGFRb with prognostic factors and outcomes were also studied.\nRESULTS: 39 patients were enrolled. First-line therapy included: sunitinib (n\u2009=\u200916), bevacizumab/interferon (n\u2009=\u200912), pazopanib (n\u2009=\u200910), sorafenib (n\u2009=\u20091). After a median follow-up of 37\u00a0months, 6-month PFS rate was 50.9% [95% confidence interval (CI) 33.8-65.7], median time to progression 6.8 months (95% CI 5.5-9.2) and median overall survival (OS) 18.2 months (95% CI 12.9-27.2). Objective response rate was 27%. The most common AEs were metabolic (33%), renal (8%) and gastrointestinal (GI) (7%). The most common grade 3-5 AEs were GI (18%), infections (14%) and metabolic (25%). Toxicity was the most frequent cause of treatment discontinuation (40%). FGFb levels were associated with OS.\nCONCLUSIONS: In concert with recent data, our study confirms the efficacy of anti-VEGF/anti-mTOR combination in mRCC relapsing after anti-VEGF therapy. Toxicity was considerable leading to high rate of treatment discontinuations.\nTRIAL REGISTRATION: ClinicalTrials.gov: NCT01264341.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s10147-018-1361-9", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1312225", 
        "issn": [
          "1341-9625", 
          "1437-7772"
        ], 
        "name": "International Journal of Clinical Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "24"
      }
    ], 
    "name": "The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study", 
    "pagination": "411-419", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "04d09af5d18ca5d59db066c3b56ec6226954c61d94ef0d90f1f668806b241995"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30374686"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9616295"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10147-018-1361-9"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1107897433"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10147-018-1361-9", 
      "https://app.dimensions.ai/details/publication/pub.1107897433"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T13:29", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000370_0000000370/records_46747_00000003.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs10147-018-1361-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10147-018-1361-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10147-018-1361-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10147-018-1361-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10147-018-1361-9'


 

This table displays all metadata directly associated to this object as RDF triples.

255 TRIPLES      21 PREDICATES      59 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10147-018-1361-9 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author Nb34128bbe33d4273afd7df8f146694d0
4 schema:citation sg:pub.10.1007/s00280-014-2668-5
5 sg:pub.10.1038/20459
6 https://app.dimensions.ai/details/publication/pub.1074847514
7 https://app.dimensions.ai/details/publication/pub.1079263967
8 https://doi.org/10.1002/cncr.25219
9 https://doi.org/10.1016/j.ccr.2005.09.005
10 https://doi.org/10.1016/j.clgc.2016.02.007
11 https://doi.org/10.1016/j.ejca.2011.11.027
12 https://doi.org/10.1016/s0140-6736(07)61904-7
13 https://doi.org/10.1016/s0140-6736(08)61039-9
14 https://doi.org/10.1016/s0165-4608(96)00296-8
15 https://doi.org/10.1016/s1470-2045(11)70124-3
16 https://doi.org/10.1016/s1470-2045(13)70093-7
17 https://doi.org/10.1016/s1470-2045(14)70030-0
18 https://doi.org/10.1016/s1470-2045(15)00290-9
19 https://doi.org/10.1016/s1470-2045(16)30107-3
20 https://doi.org/10.1056/nejmoa065044
21 https://doi.org/10.1056/nejmoa1510665
22 https://doi.org/10.1093/annonc/mdv170
23 https://doi.org/10.1111/1759-7714.12202
24 https://doi.org/10.1111/j.1524-475x.2008.00410.x
25 https://doi.org/10.1158/0008-5472.can-06-4102
26 https://doi.org/10.1158/1535-7163.mct-06-0071
27 https://doi.org/10.1172/jci24612
28 https://doi.org/10.1200/jco.2005.01.186
29 https://doi.org/10.1200/jco.2009.23.9764
30 https://doi.org/10.1200/jco.2013.50.5305
31 https://doi.org/10.1200/jco.2014.60.7341
32 https://doi.org/10.1200/jco.2016.70.7398
33 https://doi.org/10.3816/cgc.2008.n.002
34 schema:datePublished 2019-04
35 schema:datePublishedReg 2019-04-01
36 schema:description BACKGROUND: Vascular endothelial growth factor (VEGF) targeting represents the standard first-line therapy for metastatic renal-cell carcinoma (mRCC), while blocking the mammalian target of rapamycin (mTOR) is effective in relapsed disease. Since continuing blockade of VEGF may be of value, we studied the combination of bevacizumab with temsirolimus in mRCC patients relapsing after first-line treatment. METHODS: A prospective, phase II study of the combination of bevacizumab (10 mg/kg, every 2 weeks) with temsirolimus (25 mg weekly) in patients with mRCC who failed first-line anti-VEGF treatment. 6-month progression-free survival (PFS) rate was the primary end point. The association of VEGFa, VEGFR2, fibroblast growth factor (FGF) b, platelet-derived growth factor receptor (PDGFR) a and PDGFRb with prognostic factors and outcomes were also studied. RESULTS: 39 patients were enrolled. First-line therapy included: sunitinib (n = 16), bevacizumab/interferon (n = 12), pazopanib (n = 10), sorafenib (n = 1). After a median follow-up of 37 months, 6-month PFS rate was 50.9% [95% confidence interval (CI) 33.8-65.7], median time to progression 6.8 months (95% CI 5.5-9.2) and median overall survival (OS) 18.2 months (95% CI 12.9-27.2). Objective response rate was 27%. The most common AEs were metabolic (33%), renal (8%) and gastrointestinal (GI) (7%). The most common grade 3-5 AEs were GI (18%), infections (14%) and metabolic (25%). Toxicity was the most frequent cause of treatment discontinuation (40%). FGFb levels were associated with OS. CONCLUSIONS: In concert with recent data, our study confirms the efficacy of anti-VEGF/anti-mTOR combination in mRCC relapsing after anti-VEGF therapy. Toxicity was considerable leading to high rate of treatment discontinuations. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01264341.
37 schema:genre research_article
38 schema:inLanguage en
39 schema:isAccessibleForFree false
40 schema:isPartOf N2299075849724b46a0c5b2951d4e0c5a
41 N6d986443ba384cc783b647fa21257429
42 sg:journal.1312225
43 schema:name The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study
44 schema:pagination 411-419
45 schema:productId N17fc409f6de84176842d6ea483471424
46 N1eb8e850c36845649a00b6588f1cce83
47 N8821addeabab4afe9decf52d77ff10ce
48 N9974eb97618c4e979f5eb0a0a99b06ab
49 Nba8385262bee4ca2ac3ece572386bac7
50 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107897433
51 https://doi.org/10.1007/s10147-018-1361-9
52 schema:sdDatePublished 2019-04-11T13:29
53 schema:sdLicense https://scigraph.springernature.com/explorer/license/
54 schema:sdPublisher Nff70779c9f5040ceb9106afa781ab166
55 schema:url https://link.springer.com/10.1007%2Fs10147-018-1361-9
56 sgo:license sg:explorer/license/
57 sgo:sdDataset articles
58 rdf:type schema:ScholarlyArticle
59 N090efe8eedd74f8495cd2e29dec9cf18 rdf:first sg:person.01326021733.68
60 rdf:rest N8866a741bc1440e58826d47f67f7dff1
61 N0e4298e6844d4e7baa1045860d189e29 rdf:first sg:person.01332741603.72
62 rdf:rest N284cd4f0a7624e649f6697b54a5626dc
63 N131df5ddcfbf43899c6567ddf7ea8a11 rdf:first sg:person.0654575012.61
64 rdf:rest Na2531284fb2e4f128f59ac8ecd3155f4
65 N14418c450a22482b8b99f644e4542438 rdf:first sg:person.013666511457.46
66 rdf:rest N0e4298e6844d4e7baa1045860d189e29
67 N17fc409f6de84176842d6ea483471424 schema:name pubmed_id
68 schema:value 30374686
69 rdf:type schema:PropertyValue
70 N1eb8e850c36845649a00b6588f1cce83 schema:name dimensions_id
71 schema:value pub.1107897433
72 rdf:type schema:PropertyValue
73 N2299075849724b46a0c5b2951d4e0c5a schema:issueNumber 4
74 rdf:type schema:PublicationIssue
75 N284cd4f0a7624e649f6697b54a5626dc rdf:first sg:person.0723540466.15
76 rdf:rest Ndc97906081a64ee6bc3f3f9411ec6500
77 N407e75dc7d90476099044408cf91ee81 schema:name Department of Urology, General Hospital Konstantopouleio Agia Olga, Athens, Greece
78 rdf:type schema:Organization
79 N4e7c31cf4b344c3c84b4e2ac87dd0cd6 schema:name Division of Oncology, Department of Medicine, University Hospital, University of Patras Medical School, Patras, Greece
80 rdf:type schema:Organization
81 N6d986443ba384cc783b647fa21257429 schema:volumeNumber 24
82 rdf:type schema:PublicationVolume
83 N7510ad28b24c48719a9d8196fb814f0a rdf:first sg:person.01272512015.05
84 rdf:rest N090efe8eedd74f8495cd2e29dec9cf18
85 N81454777ce074f6c9e27910ae2cbba78 schema:affiliation https://www.grid.ac/institutes/grid.5216.0
86 schema:familyName Gavalas
87 schema:givenName Nikolaos
88 rdf:type schema:Person
89 N8821addeabab4afe9decf52d77ff10ce schema:name doi
90 schema:value 10.1007/s10147-018-1361-9
91 rdf:type schema:PropertyValue
92 N8866a741bc1440e58826d47f67f7dff1 rdf:first sg:person.0677251261.67
93 rdf:rest Ne46fc8d585ff41768f8c0e8b2c9be3e3
94 N9453162d6bda474fb45391dc9d821929 schema:name Department of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece
95 rdf:type schema:Organization
96 N9974eb97618c4e979f5eb0a0a99b06ab schema:name nlm_unique_id
97 schema:value 9616295
98 rdf:type schema:PropertyValue
99 Na2531284fb2e4f128f59ac8ecd3155f4 rdf:first N81454777ce074f6c9e27910ae2cbba78
100 rdf:rest N7510ad28b24c48719a9d8196fb814f0a
101 Nb34128bbe33d4273afd7df8f146694d0 rdf:first sg:person.01022220655.45
102 rdf:rest N131df5ddcfbf43899c6567ddf7ea8a11
103 Nba8385262bee4ca2ac3ece572386bac7 schema:name readcube_id
104 schema:value 04d09af5d18ca5d59db066c3b56ec6226954c61d94ef0d90f1f668806b241995
105 rdf:type schema:PropertyValue
106 Ndc97906081a64ee6bc3f3f9411ec6500 rdf:first sg:person.0601312360.10
107 rdf:rest Neb6cf534487d4b12823b8c35397114ce
108 Ne46fc8d585ff41768f8c0e8b2c9be3e3 rdf:first sg:person.01303065611.95
109 rdf:rest Ned660ae6db3f42a4a1ad697f98d92bb5
110 Ne791fb8ea39a404da32883a5b8487994 schema:name Third Department of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece
111 rdf:type schema:Organization
112 Neb6cf534487d4b12823b8c35397114ce rdf:first sg:person.01046642035.29
113 rdf:rest rdf:nil
114 Ned660ae6db3f42a4a1ad697f98d92bb5 rdf:first sg:person.013652471530.87
115 rdf:rest N14418c450a22482b8b99f644e4542438
116 Nff70779c9f5040ceb9106afa781ab166 schema:name Springer Nature - SN SciGraph project
117 rdf:type schema:Organization
118 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
119 schema:name Medical and Health Sciences
120 rdf:type schema:DefinedTerm
121 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
122 schema:name Clinical Sciences
123 rdf:type schema:DefinedTerm
124 sg:journal.1312225 schema:issn 1341-9625
125 1437-7772
126 schema:name International Journal of Clinical Oncology
127 rdf:type schema:Periodical
128 sg:person.01022220655.45 schema:affiliation https://www.grid.ac/institutes/grid.5216.0
129 schema:familyName Bamias
130 schema:givenName Aristotelis
131 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01022220655.45
132 rdf:type schema:Person
133 sg:person.01046642035.29 schema:affiliation https://www.grid.ac/institutes/grid.5216.0
134 schema:familyName Dimopoulos
135 schema:givenName Meletios-Athanasios
136 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01046642035.29
137 rdf:type schema:Person
138 sg:person.01272512015.05 schema:affiliation https://www.grid.ac/institutes/grid.5216.0
139 schema:familyName Tzannis
140 schema:givenName Kimon
141 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01272512015.05
142 rdf:type schema:Person
143 sg:person.01303065611.95 schema:affiliation N4e7c31cf4b344c3c84b4e2ac87dd0cd6
144 schema:familyName Koutras
145 schema:givenName Angelos
146 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01303065611.95
147 rdf:type schema:Person
148 sg:person.01326021733.68 schema:affiliation Ne791fb8ea39a404da32883a5b8487994
149 schema:familyName Samantas
150 schema:givenName Epaminontas
151 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01326021733.68
152 rdf:type schema:Person
153 sg:person.01332741603.72 schema:affiliation https://www.grid.ac/institutes/grid.5216.0
154 schema:familyName Koutsoukos
155 schema:givenName Konstantinos
156 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01332741603.72
157 rdf:type schema:Person
158 sg:person.013652471530.87 schema:affiliation N407e75dc7d90476099044408cf91ee81
159 schema:familyName Gkerzelis
160 schema:givenName Ioannis
161 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013652471530.87
162 rdf:type schema:Person
163 sg:person.013666511457.46 schema:affiliation https://www.grid.ac/institutes/grid.5216.0
164 schema:familyName Kostouros
165 schema:givenName Euthymios
166 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013666511457.46
167 rdf:type schema:Person
168 sg:person.0601312360.10 schema:affiliation https://www.grid.ac/institutes/grid.4793.9
169 schema:familyName Fountzilas
170 schema:givenName George
171 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601312360.10
172 rdf:type schema:Person
173 sg:person.0654575012.61 schema:affiliation https://www.grid.ac/institutes/grid.4793.9
174 schema:familyName Karavasilis
175 schema:givenName Vasilios
176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0654575012.61
177 rdf:type schema:Person
178 sg:person.0677251261.67 schema:affiliation N9453162d6bda474fb45391dc9d821929
179 schema:familyName Aravantinos
180 schema:givenName Gerasimos
181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0677251261.67
182 rdf:type schema:Person
183 sg:person.0723540466.15 schema:affiliation https://www.grid.ac/institutes/grid.5216.0
184 schema:familyName Zagouri
185 schema:givenName Flora
186 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723540466.15
187 rdf:type schema:Person
188 sg:pub.10.1007/s00280-014-2668-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047451975
189 https://doi.org/10.1007/s00280-014-2668-5
190 rdf:type schema:CreativeWork
191 sg:pub.10.1038/20459 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020261903
192 https://doi.org/10.1038/20459
193 rdf:type schema:CreativeWork
194 https://app.dimensions.ai/details/publication/pub.1074847514 schema:CreativeWork
195 https://app.dimensions.ai/details/publication/pub.1079263967 schema:CreativeWork
196 https://doi.org/10.1002/cncr.25219 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017587632
197 rdf:type schema:CreativeWork
198 https://doi.org/10.1016/j.ccr.2005.09.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040672904
199 rdf:type schema:CreativeWork
200 https://doi.org/10.1016/j.clgc.2016.02.007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020929346
201 rdf:type schema:CreativeWork
202 https://doi.org/10.1016/j.ejca.2011.11.027 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021703405
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1016/s0140-6736(07)61904-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010511397
205 rdf:type schema:CreativeWork
206 https://doi.org/10.1016/s0140-6736(08)61039-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045744105
207 rdf:type schema:CreativeWork
208 https://doi.org/10.1016/s0165-4608(96)00296-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040691028
209 rdf:type schema:CreativeWork
210 https://doi.org/10.1016/s1470-2045(11)70124-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046924268
211 rdf:type schema:CreativeWork
212 https://doi.org/10.1016/s1470-2045(13)70093-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017252421
213 rdf:type schema:CreativeWork
214 https://doi.org/10.1016/s1470-2045(14)70030-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033030655
215 rdf:type schema:CreativeWork
216 https://doi.org/10.1016/s1470-2045(15)00290-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048871630
217 rdf:type schema:CreativeWork
218 https://doi.org/10.1016/s1470-2045(16)30107-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031150467
219 rdf:type schema:CreativeWork
220 https://doi.org/10.1056/nejmoa065044 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007947936
221 rdf:type schema:CreativeWork
222 https://doi.org/10.1056/nejmoa1510665 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019970557
223 rdf:type schema:CreativeWork
224 https://doi.org/10.1093/annonc/mdv170 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014223550
225 rdf:type schema:CreativeWork
226 https://doi.org/10.1111/1759-7714.12202 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012855455
227 rdf:type schema:CreativeWork
228 https://doi.org/10.1111/j.1524-475x.2008.00410.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1016786299
229 rdf:type schema:CreativeWork
230 https://doi.org/10.1158/0008-5472.can-06-4102 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022228675
231 rdf:type schema:CreativeWork
232 https://doi.org/10.1158/1535-7163.mct-06-0071 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012687077
233 rdf:type schema:CreativeWork
234 https://doi.org/10.1172/jci24612 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011051285
235 rdf:type schema:CreativeWork
236 https://doi.org/10.1200/jco.2005.01.186 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064204187
237 rdf:type schema:CreativeWork
238 https://doi.org/10.1200/jco.2009.23.9764 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052849919
239 rdf:type schema:CreativeWork
240 https://doi.org/10.1200/jco.2013.50.5305 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011437471
241 rdf:type schema:CreativeWork
242 https://doi.org/10.1200/jco.2014.60.7341 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008993365
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1200/jco.2016.70.7398 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083840373
245 rdf:type schema:CreativeWork
246 https://doi.org/10.3816/cgc.2008.n.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048226250
247 rdf:type schema:CreativeWork
248 https://www.grid.ac/institutes/grid.4793.9 schema:alternateName Aristotle University of Thessaloniki
249 schema:name Aristotle University of Thessaloniki, Thessaloníki, Greece
250 Department of Medical Oncology, Papageorgiou Hospital, School of Health Sciences, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloníki, Greece
251 Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloníki, Greece
252 rdf:type schema:Organization
253 https://www.grid.ac/institutes/grid.5216.0 schema:alternateName National and Kapodistrian University of Athens
254 schema:name Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens, 80 Vas. Sofias Ave, 115 28, Athens, Greece
255 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...